Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The source problem
I June 9, 2026 Return policy Shipping Policy 4.6 (25) (3) (1) (2) 21% off 29% off 6% off Exclusive offer available (151) (99) (51) (55) (31) (85) (39) (13) (18) 15% off (7) (9) 4.6 (58) (33) (12) (14) (11) 17% off (4) 10% off 25% off (2.7K) (565) 13% off (82) (203) (353) (251) (109) (169) (211) (5) (35) (68) 4.8 (48.9K) (23.5K) (16.1K) (3.5K) (3.4K) (943) (798) (2.8K) (171) (1.1K) (756) (931) (956) 4.5 (179.7K) 4.7 (228.2K) 4.6 (11.9K) 4.3 (428.8K) 4.5 (94.3K) 4.7 (173.6K) 4.6 (189.1K) 4.9 (406.9K) 4.4 (9.4K) 4.7 (151.3K)
The FDAs decision was based on the Phase III APPLAUSE-IgAN study, in which treatment with Fabhalta cut proteinuria by 44% through nine months of follow-up, while placebo comparators saw only a 9% reduction in proteinuria
154 OgasawaraH.DoiT.DoyaK.KawatoM
it does not constitute evidence of safety or efficacy in humans
US$ 21.91
US$ 24.42
US$ 24.56
US$ 21.40
US$ 22.03
US$ 28.73
US$ 20.05
US$ 20.37
US$ 27.82